New FDA Medication Approval – Anktiva for NMIBC

On April 22, 2024, the US Food and Drug Administration (FDA) approved ImmunityBio’s first-in-class interleukin-15 superagonist (IL-15) nogapendekin alfa inbakicept-pmln (Anktiva), plus bacillus Calmette-Guérin (BCG), for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.  Designated an FDA Breakthrough Therapy, the novel immunotherapy […]